Effectiveness and safety of erlotinib in 2 patients with carcinoma of the cervix;Efectividad y seguridad de erlotinib en 2 pacientes con carcinoma de cérvix uterino

Farmacia Hospitalaria

Volumn 33, Issue 2, 2009, Pages 96-99

  Perez Rodrigo I ^a   Albornoz Lopez R ^a   Soto Rojas, M ^b   Fernandez Garcia I ^a   Torres Degayon V ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

Author keywords

Carcinoma of the cervix; Compassionate use; Effectiveness; Erlotinib; Safety

Indexed keywords

CISPLATIN; ERLOTINIB; NAVELBINE; TOPOTECAN;

ACNE; ADULT; ARTICLE; CASE REPORT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL RECORD; PROGRESSION FREE SURVIVAL; UTERINE CERVIX CARCINOMA;

EID: 68349116013     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(09)70994-8     Document Type: Editorial

References (9)

1. F. Kamanger, G.M. Dores, and W.F. Anderson Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2006 2137 2150
2. J.K. Chan, and J.S. Berek Impact of the human papilloma vaccine on cervical cancer J Clin Oncol 25 2007 2975 2982
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer 2008. Disponible en: http://www.nccn.org
4. Open database. Search Erlotinib [consultado, 8 Sep 2008]. Disponible en: http://clinicaltrials.gov
5. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
6. G.A. Omura, J.A. Blessing, L. Vaccarello, M.L. Berman, D.L. Clarke-Pearson, and D.G. Mutch Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study J Clin Oncol 15 1997 165 171
7. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 22 2004 3113 3119 (Pubitemid 41103724)
8. H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr, J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with o without topotecan in carcinoma of the uterine cerviz: a gynecologic oncology group study J Clin Oncol 23 2005 4626 4633 (Pubitemid 46224065)
9. A. Goncalves, M. Fabbro, C. Lhommé, L. Gladieff, J.M. Extra, and A. Floquet A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer Gynecol Oncol 108 2008 42 46